{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:12:24Z","timestamp":1789726344503,"version":"4.0.1"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Insulin degludec\/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin degludec (IDeg), which provides long-lasting basal insulin coverage, and insulin aspart (IAsp), which targets post-prandial glucose. This expert panel aimed to provide a practical and implementable guidance document to assist clinicians in prescribing IDegAsp in the diabetes management with respect to different patient populations including children and adults with type 1 diabetes (T1D) or type 2 diabetes (T2D) as well as pregnant, elderly and hospitalized patients and varying practice patterns (insulin-naive, insulin-treated, switching from basal, basal bolus and premix regimens). The experts recommended that IDegAsp can be used in insulin-naive T2D patients with poor glycemic control (HbA1c &amp;gt;8.5%) despite optimal oral antidiabetic drugs (OADs) as well as in insulin-treated T2D patients by switching from basal insulin, basal-bolus therapy or premixed insulins in relation to lower risk of nocturnal hypoglycemia, fewer injections and lower intraday glycemic variability, respectively. The experts considered the use of IDegAsp in children with T2D as a basal bolus alternative rather than as an alternative to basal insulin after metformin failure, use of IDegAsp in adult T1D patients as a simplified basal bolus regimen with lesser nocturnal hypoglycemia, fewer injections and better fasting plasma glucose control and in children with T1D as an alternative insulin regimen with fewer injection to increase treatment adherence. The proposed expert opinion provides practical information on use of IDegAsp in different patient populations and practice patterns to assist clinicians, which seems to compensate the need for easily implementable guidance on this novel insulin regimen.<\/jats:p>","DOI":"10.3389\/fendo.2021.616514","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T14:53:41Z","timestamp":1615560821000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Use of Insulin Degludec\/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns"],"prefix":"10.3389","volume":"12","author":[{"given":"Tevfik","family":"Demir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serap","family":"Turan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kursad","family":"Unluhizarci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oya","family":"Topaloglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tufan","family":"Tukek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Gogas Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"B1","volume-title":"IDF Diabetes Atlas","year":"2019"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.9.1551","article-title":"Population-based study of diabetes and risk characteristics in Turkey: results of the Turkish diabetes epidemiology study (TURDEP)","volume":"25","author":"Satman","year":"2002","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-013-9771-5","article-title":"TURDEP-II Study Group. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults","volume":"28","author":"Satman","year":"2013","journal-title":"Eur J Epidemiol"},{"key":"B4","unstructured":"Geneva, SwitzerlandWHO PressGlobal report on diabetes2016"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13062","article-title":"Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit","volume":"33","author":"Baxter","year":"2016","journal-title":"Diabetes Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e013763","DOI":"10.1136\/bmjopen-2016-013763","article-title":"Long-term cost reduction of routine medications following a residential programme combining physical activity and nutrition in the treatment of type 2 diabetes: a prospective cohort study","volume":"7","author":"Lanhers","year":"2017","journal-title":"BMJ Open"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"B9","first-page":"1","article-title":"Type 2 diabetes in adults: management","year":"2015","journal-title":"Nice Guideline"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00125-002-1009-0","article-title":"The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes","volume":"46","author":"Kahn","year":"2003","journal-title":"Diabetologia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-S009","article-title":"Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4158\/EP.13.S1.1","article-title":"The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management--2000 update","volume":"6","year":"2000","journal-title":"Endocr Pract"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2013.0081","article-title":"Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes","volume":"15","author":"Owens","year":"2013","journal-title":"Diabetes Technol Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01138.x","article-title":"The importance of titrating starting insulin regimens in patients with type 2 diabetes","volume":"11","author":"Garber","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905479","article-title":"Three-year efficacy of complex insulin regimens in type 2 diabetes","volume":"361","author":"Holman","year":"2009","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3460-0","article-title":"Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"58","author":"Inzucchi","year":"2015","journal-title":"Diabetologia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03605.x","article-title":"Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study","volume":"29","author":"Peyrot","year":"2012","journal-title":"Diabetes Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1185\/03007995.2011.621416","article-title":"Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes","volume":"27","author":"Ross","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2743","article-title":"Insulin therapy in people with type 2 diabetes: Opportunities and challenges","volume":"37","author":"Home","year":"2014","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1348","article-title":"Correlates of insulin injection omission","volume":"33","author":"Peyrot","year":"2010","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0022","article-title":"Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues","volume":"166","author":"Vaag","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0455-7","article-title":"A Review of Insulin Degludec\/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use","volume":"56","author":"Haahr","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S1557-0843(07)80018-2","article-title":"The Use of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: Advantages and limitations","volume":"2","author":"Rizvi","year":"2007","journal-title":"Insulin"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S87935","article-title":"Adherence to insulin treatment in insulin-na\u00efve type 2 diabetic patients initiated on different insulin regimens","volume":"9","author":"Yavuz","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S100626","article-title":"Impact of telephonic interviews on persistence and daily adherence to insulin treatment in insulin-na\u00efve type 2 diabetes patients: dropout study","volume":"10","author":"Yavuz","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2008.0019","article-title":"The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study","volume":"10","author":"Heise","year":"2008","journal-title":"Diabetes Technol Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s13300-014-0067-x","article-title":"Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues","volume":"5","author":"Kalra","year":"2014","journal-title":"Diabetes Ther"},{"key":"B29","unstructured":"Bagsv\u00e6rd, DenmarkNovo Nordisk A\/SRyzodeg (insulin degludec\/insulin aspart) summary of product characteristics2019"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-015-0106-2","article-title":"Injectable Coformulations in Diabetology","volume":"6","author":"Kalra","year":"2015","journal-title":"Diabetes Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-2503","article-title":"Insulin degludec\/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial","volume":"35","author":"Hirsch","year":"2012","journal-title":"Diabetes Care"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13068","article-title":"Safety and efficacy of insulin degludec\/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST\u00ae T1)","volume":"34","author":"Hirsch","year":"2017","journal-title":"Diabetes Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12097","article-title":"Superior glycaemic control with once-daily insulin degludec\/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial","volume":"15","author":"Onishi","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/dme.12982","article-title":"Twice-daily insulin degludec\/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-na\u00efve adults with Type 2 diabetes","volume":"33","author":"Franek","year":"2016","journal-title":"Diabetes Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2908","article-title":"BOOST: Intensify Premix I Investigators. Comparison of insulin degludec\/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial","volume":"37","author":"Fulcher","year":"2014","journal-title":"Diabetes Care"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2014.09.026","article-title":"BOOST: Intensify All Trial Investigators. Insulin degludec\/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-\/self-mixed insulin: a 26-week, randomised, treat-to-target trial","volume":"107","author":"Kaneko","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2337\/db18-91-LB","article-title":"Insulin degludec\/insulin aspart (IDegAsp) twice daily (BID) vs biphasic insulin aspart 30 (BIAsp 30) BID: a randomised trial in Chinese patients with type 2 diabetes","volume":"67","author":"Yang","year":"2018","journal-title":"Diabetes"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12609","article-title":"Treatment intensification with an insulin degludec (IDeg)\/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial","volume":"18","author":"Rodbard","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2017.11.027","article-title":"Efficacy and safety analysis of insulin degludec\/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan","volume":"135","author":"Hassanein","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13261","article-title":"The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes","volume":"20","author":"Haluz\u00edk","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14128","article-title":"Practical use of insulin degludec\/insulin aspart in a multinational setting: beyond the guidelines","volume":"22","author":"Mehta","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.182980","article-title":"Pragmatic use of insulin degludec\/insulin aspart co-formulation: A multinational consensus statement","volume":"20","author":"Kalra","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0712-2","article-title":"Multinational Consensus: Insulin Initiation with Insulin Degludec\/Aspart (IDegAsp)","volume":"35","author":"Kalra","year":"2018","journal-title":"Adv Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12821","article-title":"Clinical use of the co-formulation of insulin degludec and insulin aspart","volume":"70","author":"Kumar","year":"2016","journal-title":"Int J Clin Pract"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-014-1614-x","article-title":"Investigation of the physico-chemical properties that enable co-formulation of basal insulin degludec with fast-acting insulin aspart","volume":"32","author":"Havelund","year":"2015","journal-title":"Pharm Res"},{"key":"B47","first-page":"15","article-title":"Review of Clinical Profile of IDegAsp","volume":"63","author":"Unnikrishnan","year":"2015","journal-title":"J Assoc Physicians India"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.177416","article-title":"Insulin degludec aspart: one-year real world experience","volume":"20","author":"Kalra","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1668","article-title":"NN1250-3668 (BEGIN FLEX) Trial Investigators. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes","volume":"36","author":"Meneghini","year":"2013","journal-title":"Diabetes Care"},{"key":"B50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1586\/eem.11.86","article-title":"Insulin degludec: a novel ultra-long-acting basal insulin for use in Type 1 and 2 diabetes","volume":"7","author":"Meneghini","year":"2012","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/DHPS.S59566","article-title":"Patient safety and minimizing risk with insulin administration - role of insulin degludec","volume":"6","author":"Aye","year":"2014","journal-title":"Drug Healthc Patient Saf"},{"key":"B52","first-page":"1","article-title":"Similar glycaemic control and less nocturnal hypoglycaemia with intensification of IDegAsp QD or BD vs glargine U100 QD + IAsp 1-3 in adults with type 2 diabetes. In Proceedings of the EASD","author":"Gupta","year":"2018"},{"key":"B53","first-page":"1","article-title":"Insulin degludec\/insulin aspart (IDegAsp) twice daily (BID) vs biphasic insulin aspart 30 (BIAsp 30) BID: a randomised trial in Chinese patients with type 2 diabetes, In Proceedings of the EASD","author":"Ma","year":"2018"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e0163350","DOI":"10.1371\/journal.pone.0163350","article-title":"Efficacy and Safety of Once-Daily Insulin Degludec\/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naive Patients with Type 2 Diabetes: A Randomized Controlled Trial","volume":"11","author":"Kumar","year":"2016","journal-title":"PloS One"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1177\/193229681300700524","article-title":"A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial","volume":"7","author":"Liebl","year":"2013","journal-title":"J Diabetes Sci Technol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.10.024","article-title":"Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus","volume":"147","author":"Philis-Tsimikas","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.10.024","article-title":"Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes","volume":"14","author":"Heise","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.1058779","article-title":"Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine","volume":"11","author":"Heise","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12032","article-title":"Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials","volume":"15","author":"Ratner","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2016.06.002","article-title":"Management of postprandial glucose: Recommended targets and treatment with biphasic insulin","volume":"10","author":"Liebl","year":"2016","journal-title":"Prim Care Diabetes"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.277","article-title":"The underuse of insulin therapy in North America","volume":"18","author":"Riddle","year":"2002","journal-title":"Diabetes Metab Res Rev"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ19-0179","article-title":"Comparison of the efficacy and safety of once-daily insulin degludec\/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units\/mL) in insulin-na\u00efve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study","volume":"66","author":"Shimoda","year":"2019","journal-title":"Endocr J"},{"key":"B63","first-page":"15","volume-title":"Turkish Society of Endocrinology and Metabolism 2017 Guideline for Diagnosis, Treatment and Monitoring of Diabetes Mellitus and Its Complications","author":"Satman","year":"2016"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2019.0093","article-title":"Switching to Once-Daily Insulin Degludec\/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial","volume":"44","author":"Cho","year":"2020","journal-title":"Diabetes Metab J"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12355","article-title":"Lower rates of hypoglycemia during maintenance treatment with insulin degludec\/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes","volume":"8","author":"Christiansen","year":"2016","journal-title":"J Diabetes"},{"key":"B66","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jpeds.2004.12.042","article-title":"The global spread of type 2 diabetes mellitus in children and adolescents","volume":"146","author":"Pinhas-Hamiel","year":"2005","journal-title":"J Pediatr"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1177\/2040622314548679","article-title":"Early onset type 2 diabetes: risk factors, clinical impact and management","volume":"5","author":"Wilmot","year":"2014","journal-title":"Ther Adv Chronic Dis"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.11.029","article-title":"Rapid deterioration of insulin secretion in obese adolescents preceding the onset of type 2 diabetes","volume":"166","author":"Elder","year":"2015","journal-title":"J Pediatr"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-s212","article-title":"Type 2 diabetes in youth: epidemiology and pathophysiology","author":"D\u2019Adamo","year":"2011","journal-title":"Diabetes Care"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0052","article-title":"Evaluation and Management of Youth-Onset Type 2 Diabetes: A Position Statement by the American Diabetes Association","volume":"41","author":"Arslanian","year":"2018","journal-title":"Diabetes Care"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12724","article-title":"Efficacy and safety of a fixed combination of insulin degludec\/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial","volume":"19","author":"Battelino","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-018-0926-9","article-title":"Exposure to insulin degludec during pregnancy: report of a small series and review of the literature","volume":"42","author":"Bonora","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0532-z","article-title":"Successful Outcomes with Insulin Degludec in Pregnancy: A Case Series","volume":"10","author":"Hiranput","year":"2019","journal-title":"Diabetes Ther"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2015.21.3.243","article-title":"Association between hypoglycemia and fall-related events in type 2 diabetes mellitus: analysis of a U.S. commercial database","volume":"21","author":"Kachroo","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"B75","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2019","journal-title":"Eur Heart J"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0531-0","article-title":"Efficacy and Safety of IDegAsp Versus BIAsp 30, Both Twice Daily, in Elderly Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3 Randomized Controlled BOOST Trials","volume":"10","author":"Fulcher","year":"2019","journal-title":"Diabetes Ther"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-015-0272-y","article-title":"The distinct prandial and basal pharmacodynamics of IDegAsp observed in younger adults are preserved in elderly subjects with type 1 diabetes","volume":"32","author":"Brunner","year":"2015","journal-title":"Drugs Aging"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.616514\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T14:53:48Z","timestamp":1615560828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.616514\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":77,"alternative-id":["10.3389\/fendo.2021.616514"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.616514","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"article-number":"616514"}}